Hansoh Enters into a Collaboration with Atomwise for AI-Based Drug Discovery
Shots:
- Atomwise to receive technology access fees- option exercise fees- royalties- and income-based on sublicensing or sale of assets leading to a total deal value of ~$1.5B. The companies will develop therapies for up to eleven target protein in multiple therapeutic areas
- The agreement involves the collaboration of a scientific team of both the companies- utilizing Atomwise’s AI technology and medicinal chemistry plus protein structure expertise with Hansoh’s research- development & commercialization capabilities
- Atomwise’s technology is the first deep learning AI technology for structure-based small molecule drug discovery. Atomwise collaborated with multiple pharmaceutical & agrochemical companies as well as with Universities & hospital for its AI-based technology across 19 countries
Click here to read full press release/ article | Ref: Business Wire | Image: Atomwise
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com